4506 Stock Overview
Sumitomo Pharma Co., Ltd. engages in the manufacture and sale of pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Sumitomo Pharma Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥392.00 |
| 52 Week High | JP¥865.00 |
| 52 Week Low | JP¥324.00 |
| Beta | 0.59 |
| 1 Month Change | 0% |
| 3 Month Change | -20.49% |
| 1 Year Change | -52.88% |
| 3 Year Change | -79.25% |
| 5 Year Change | -83.77% |
| Change since IPO | -74.28% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4506 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | -3.9% | -1.0% | 1.9% |
| 1Y | -52.9% | 5.9% | 33.5% |
Return vs Industry: 4506 underperformed the JP Pharmaceuticals industry which returned 5.9% over the past year.
Return vs Market: 4506 underperformed the JP Market which returned 33.5% over the past year.
Price Volatility
| 4506 volatility | |
|---|---|
| 4506 Average Weekly Movement | 6.9% |
| Pharmaceuticals Industry Average Movement | 3.7% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in JP Market | 8.3% |
| 10% least volatile stocks in JP Market | 2.2% |
Stable Share Price: 4506's share price has been volatile over the past 3 months.
Volatility Over Time: 4506's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1897 | 6,250 | Hiroshi Nomura | www.sumitomo-pharma.com |
Sumitomo Pharma Co., Ltd. engages in the manufacture and sale of pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally. The company offers pharmaceutical products, such as therapeutic agents for Parkinson’s disease, uterine fibroids, depression, type 2 diabetes, systemic fungal infection, hypertension, pruritus, advanced prostate cancer, overactive bladder, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It provides products for atypical antipsychotic, cultured thymus tissue for pediatric congenital athymia, antiepileptic, and carbapenem antibiotic; and Fabry disease drugs.
Sumitomo Pharma Co., Ltd. Fundamentals Summary
| 4506 fundamental statistics | |
|---|---|
| Market cap | JP¥161.70b |
| Earnings (TTM) | -JP¥173.72b |
| Revenue (TTM) | JP¥330.31b |
0.5x
P/S Ratio-0.9x
P/E RatioIs 4506 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4506 income statement (TTM) | |
|---|---|
| Revenue | JP¥330.31b |
| Cost of Revenue | JP¥132.34b |
| Gross Profit | JP¥197.96b |
| Other Expenses | JP¥371.68b |
| Earnings | -JP¥173.72b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 14, 2024
| Earnings per share (EPS) | -437.26 |
| Gross Margin | 59.93% |
| Net Profit Margin | -52.59% |
| Debt/Equity Ratio | 119.9% |
How did 4506 perform over the long term?
See historical performance and comparison